AN2 Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 41
- Market Cap
- $34.9M
- Introduction
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
First-in-Human Trial of Oral AN2-502998
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- AN2 Therapeutics, Inc
- Target Recruit Count
- 64
- Registration Number
- NCT07024589
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis
- Conditions
- Melioidosis
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- AN2 Therapeutics, Inc
- Target Recruit Count
- 200
- Registration Number
- NCT06089668
- Locations
- 🇱🇦
Mahosot Hospital, Vientiane, Lao People's Democratic Republic
🇹🇭Srinagarind Hospital, Khon Kaen, Thailand
🇹🇭Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand
A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- AN2 Therapeutics, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT05995444
- Locations
- 🇺🇸
423001, Tempe, Arizona, United States
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
- Conditions
- MAC Lung DiseaseTreatment Refractory MAC Lung Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AN2 Therapeutics, Inc
- Target Recruit Count
- 177
- Registration Number
- NCT05327803
- Locations
- 🇺🇸
423032, Birmingham, Alabama, United States
🇺🇸423037, Tucson, Arizona, United States
🇺🇸423070, Sacramento, California, United States
A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- AN2 Therapeutics, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT05283746
- Locations
- 🇺🇸
Advanced Pharma CR, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Nucleus Network, Saint Paul, Minnesota, United States
- Prev
- 1
- 2
- Next
News
AN2 Therapeutics Completes 200-Patient Study Revealing 40% Mortality Rate in Acute Melioidosis
AN2 Therapeutics completed a 200-patient observational study in acute melioidosis, revealing a striking mortality rate of nearly 40% by Day 90 despite standard of care treatment.
Aligos Therapeutics Strengthens CMC Leadership with Industry Veteran Ahead of Phase 2 Trial
Aligos Therapeutics has appointed Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), bringing over 20 years of pharmaceutical development experience to the company.
AN2 Therapeutics Shifts Phase 3 MAC Lung Disease Trial to Quality of Life Endpoint
AN2 Therapeutics has selected Quality of Life-Bronchiectasis (QOL-B) respiratory domain as the new primary efficacy endpoint for their Phase 3 EBO-301 trial in treatment-refractory MAC lung disease.
AN2 Therapeutics' Epetraborole Shows Promise in Phase 2 NTM Lung Disease Trial
Phase 2 clinical trials of epetraborole demonstrated significant improvements in respiratory quality of life for patients with refractory MAC NTM lung disease, supporting advancement to Phase 3 studies.